Media
Follow our progress and stay up to date with our press releases and media coverage.
Press Releases
GeneVentiv Welcomes New Advisors
August 29, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has added Robert Baffi and Deborah Wild as Advisors as the Company prepares...
GeneVentiv Invited to Present in Labcorp’s Symposium at the 26th Annual Meeting of the American Society of Cell and Gene Therapy
April 12, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present as part of Labcorp’s symposium at the 26th Annual...
GeneVentiv Invited to Present at The National Hemophilia Foundation’s 17th Workshop
February 21, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present new data from pre-clinical studies of its lead gene...
GeneVentiv Expands Management Team and Board of Directors
January 23, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has expanded the Company’s management team and board of directors with the...
GeneVentiv Therapeutics Receives Funding from the North Carolina Biotechnology Center
June 7, 2022 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced the award of a $250,000 Strategic Research Loan (SRL) from the North Carolina...
GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the treatment of Hemophilia A or B with or without inhibitors
Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
In the News
Rare Disease Advisor – An Interview with Damon Race, President and CEO of GeneVentiv Therapeutics
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Damon Race, CEO of GeneVentiv Therapeutics. The North Carolina-based startup hopes to develop a universal gene therapy that will benefit patients with hemophilia A or B with or without...
UNC-Chapel Hill gene therapy spinout raises $1.4 million
By Zac Ezzone – Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...
Bootstrapped UNC spinout lands $300K for gene therapy work
The Old Well on the UNC-Chapel Hill campus. Mehmet Demirci By Zac Ezzone - Staff writer June 14, 2022, 08:52am EDT After bootstrapping for nearly two years, the CEO of a UNC-Chapel Hill spinout developing gene therapies has received some financial support. In March,...
Triangle gene therapy startup GeneVentiv Therapeutics awarded $250K loan from NC Biotech Center
Pixabay image by Jason Parker — June 8, 2022 RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC). The loan will enable the...
GeneVentiv Therapeutics Wins KickStart Commercialization Grant
Shar March 16, 2022 By Shellie Edge KickStart Venture Services – the premier life sciences startup program and accelerator from Innovate Carolina – has awarded commercialization grants to two UNC-affiliated startup companies, Elipsys, LLC, and GeneVentiv Therapeutics,...
GeneVentiv Therapeutics selected to pitch at CED’s Venture Connect
https://wraltechwire.com/2022/03/07/startup-spotlight-presenting-companies-to-pitch-at-ceds-venture-connect/
Startup Spotlight: UNC-linked startup is giving hope to those with hemophilia
by Shellie Edge, Innovate Carolina — February 8, 2022 . Editor’s note: Startup Spotlight is a regular weekly feature in WRAL TechWire. This week’s feature comes from UNC-Chapel Hill’s Innovate Carolina. +++ CHAPEL HILL – For most people, a small cut on the hand or...
Universal hope for hemophilia
Universal hope for hemophilia Current hemophilia treatments have limitations for a significant number of patients. That’s why UNC-connected startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia,...
Potential Gene Therapy GENV-HEM Earns Orphan Drug Status
Hemophilia News Today by Marta Figueiredo PhD | November 3, 2021 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without...